Monitor patient enrollment updates and any early efficacy signals from Part B, which could drive volatility given the $2M market cap. The DSMB approval removes a near-term binary risk but does not change the fundamental pre-revenue status — any positive data readout remains months away.
Price Chart
Executive Summary
Clearmind Medicine received DSMB approval to advance its Phase I/II trial of CMND-100 for Alcohol Use Disorder to Parts B and C after Part A met its primary safety endpoint. The approval enables first-in-patient testing but does not guarantee efficacy or eventual commercialization.
Key Facts
- DSMB unanimously approved advancing Phase I/II trial of CMND-100 to Parts B and C
- Part A achieved primary safety endpoint with favorable profile across all dose levels in healthy participants
- Part B will evaluate CMND-100 in patients with moderate to severe AUD for the first time
- Part C will test 160 mg daily dose over 5 days in healthy participants in double-blind, placebo-controlled segment
- Trial conducted at Johns Hopkins, Yale, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center
- CMND-100 is a non-hallucinogenic oral formulation of MEAI (5-methoxy-2-aminoindane)
- Company has 19 patent families including 32 granted patents
- Market cap is approximately $2M
Financial Impact
No financial data provided; company is pre-revenue clinical-stage biotech
Risk Factors
- CMND-100 may fail to show efficacy in AUD patients in Part B
- Clinical trial enrollment delays or safety issues in Parts B/C
- Company has minimal cash runway visibility — no financial data in this release
- Regulatory pathway to approval is long and uncertain for a Phase I/II asset
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344415 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers